Skip to main content

Main menu

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions

Understanding the impact of pulmonary arterial hypertension on patients' and carers' lives

Loïc Guillevin, Iain Armstrong, Rino Aldrighetti, Luke S. Howard, Henrik Ryftenius, Aryeh Fischer, Sandra Lombardi, Sean Studer, Pisana Ferrari
European Respiratory Review 2013 22: 535-542; DOI: 10.1183/09059180.00005713
Loïc Guillevin
1Service de Médecine Interne, Hôpital Cochin, Paris, France. 2Pulmonary Hypertension Association UK, Rotherham, and 4National Pulmonary Hypertension Service, Hammersmith Hospital, Imperial College London, London, UK. 3Pulmonary Hypertension Association US, Silver Spring, MD, 6Division of Rheumatology, Dept of Medicine, National Jewish Health, Denver, CO, 7UCSD Medical Center, San Diego, CA, and 8Woodhull Medical Center, New York University, New York, NY, USA. 5Lung Allergy Clinic, Karolinska University Hospital, Stockholm, Sweden. 9Pulmonary Hypertension Association Europe, Vienna, Austria.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: loic.guillevin@cch.ap-hop-paris.fr
Iain Armstrong
1Service de Médecine Interne, Hôpital Cochin, Paris, France. 2Pulmonary Hypertension Association UK, Rotherham, and 4National Pulmonary Hypertension Service, Hammersmith Hospital, Imperial College London, London, UK. 3Pulmonary Hypertension Association US, Silver Spring, MD, 6Division of Rheumatology, Dept of Medicine, National Jewish Health, Denver, CO, 7UCSD Medical Center, San Diego, CA, and 8Woodhull Medical Center, New York University, New York, NY, USA. 5Lung Allergy Clinic, Karolinska University Hospital, Stockholm, Sweden. 9Pulmonary Hypertension Association Europe, Vienna, Austria.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rino Aldrighetti
1Service de Médecine Interne, Hôpital Cochin, Paris, France. 2Pulmonary Hypertension Association UK, Rotherham, and 4National Pulmonary Hypertension Service, Hammersmith Hospital, Imperial College London, London, UK. 3Pulmonary Hypertension Association US, Silver Spring, MD, 6Division of Rheumatology, Dept of Medicine, National Jewish Health, Denver, CO, 7UCSD Medical Center, San Diego, CA, and 8Woodhull Medical Center, New York University, New York, NY, USA. 5Lung Allergy Clinic, Karolinska University Hospital, Stockholm, Sweden. 9Pulmonary Hypertension Association Europe, Vienna, Austria.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luke S. Howard
1Service de Médecine Interne, Hôpital Cochin, Paris, France. 2Pulmonary Hypertension Association UK, Rotherham, and 4National Pulmonary Hypertension Service, Hammersmith Hospital, Imperial College London, London, UK. 3Pulmonary Hypertension Association US, Silver Spring, MD, 6Division of Rheumatology, Dept of Medicine, National Jewish Health, Denver, CO, 7UCSD Medical Center, San Diego, CA, and 8Woodhull Medical Center, New York University, New York, NY, USA. 5Lung Allergy Clinic, Karolinska University Hospital, Stockholm, Sweden. 9Pulmonary Hypertension Association Europe, Vienna, Austria.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Henrik Ryftenius
1Service de Médecine Interne, Hôpital Cochin, Paris, France. 2Pulmonary Hypertension Association UK, Rotherham, and 4National Pulmonary Hypertension Service, Hammersmith Hospital, Imperial College London, London, UK. 3Pulmonary Hypertension Association US, Silver Spring, MD, 6Division of Rheumatology, Dept of Medicine, National Jewish Health, Denver, CO, 7UCSD Medical Center, San Diego, CA, and 8Woodhull Medical Center, New York University, New York, NY, USA. 5Lung Allergy Clinic, Karolinska University Hospital, Stockholm, Sweden. 9Pulmonary Hypertension Association Europe, Vienna, Austria.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aryeh Fischer
1Service de Médecine Interne, Hôpital Cochin, Paris, France. 2Pulmonary Hypertension Association UK, Rotherham, and 4National Pulmonary Hypertension Service, Hammersmith Hospital, Imperial College London, London, UK. 3Pulmonary Hypertension Association US, Silver Spring, MD, 6Division of Rheumatology, Dept of Medicine, National Jewish Health, Denver, CO, 7UCSD Medical Center, San Diego, CA, and 8Woodhull Medical Center, New York University, New York, NY, USA. 5Lung Allergy Clinic, Karolinska University Hospital, Stockholm, Sweden. 9Pulmonary Hypertension Association Europe, Vienna, Austria.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sandra Lombardi
1Service de Médecine Interne, Hôpital Cochin, Paris, France. 2Pulmonary Hypertension Association UK, Rotherham, and 4National Pulmonary Hypertension Service, Hammersmith Hospital, Imperial College London, London, UK. 3Pulmonary Hypertension Association US, Silver Spring, MD, 6Division of Rheumatology, Dept of Medicine, National Jewish Health, Denver, CO, 7UCSD Medical Center, San Diego, CA, and 8Woodhull Medical Center, New York University, New York, NY, USA. 5Lung Allergy Clinic, Karolinska University Hospital, Stockholm, Sweden. 9Pulmonary Hypertension Association Europe, Vienna, Austria.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sean Studer
1Service de Médecine Interne, Hôpital Cochin, Paris, France. 2Pulmonary Hypertension Association UK, Rotherham, and 4National Pulmonary Hypertension Service, Hammersmith Hospital, Imperial College London, London, UK. 3Pulmonary Hypertension Association US, Silver Spring, MD, 6Division of Rheumatology, Dept of Medicine, National Jewish Health, Denver, CO, 7UCSD Medical Center, San Diego, CA, and 8Woodhull Medical Center, New York University, New York, NY, USA. 5Lung Allergy Clinic, Karolinska University Hospital, Stockholm, Sweden. 9Pulmonary Hypertension Association Europe, Vienna, Austria.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pisana Ferrari
1Service de Médecine Interne, Hôpital Cochin, Paris, France. 2Pulmonary Hypertension Association UK, Rotherham, and 4National Pulmonary Hypertension Service, Hammersmith Hospital, Imperial College London, London, UK. 3Pulmonary Hypertension Association US, Silver Spring, MD, 6Division of Rheumatology, Dept of Medicine, National Jewish Health, Denver, CO, 7UCSD Medical Center, San Diego, CA, and 8Woodhull Medical Center, New York University, New York, NY, USA. 5Lung Allergy Clinic, Karolinska University Hospital, Stockholm, Sweden. 9Pulmonary Hypertension Association Europe, Vienna, Austria.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Pulmonary arterial hypertension (PAH) is a rare, debilitating and rapidly progressive disease. Although there have been important medical advances in PAH management, the search for a cure continues. Despite an increased understanding of the disease, data on the wider effect of PAH on patients and carers, beyond the clinical symptoms, are still limited. In order to explore this, a large-scale international survey investigated four key areas affected by PAH (physical and practical, emotional, social, and information needs) and provides new insight into patients’ and carers’ experiences of living with the disease. The results from the survey highlight not only the limited ability of patients to carry out everyday tasks, but also the financial impact and social isolation experienced by both patients and carers. The study confirmed that a decline in a patient’s World Health Organization functional class, which indicates an increase in clinical severity of the disease, is associated with greater limitations. Results from the survey demonstrate the need for multidisciplinary PAH management and a comprehensive standard of care to assess and improve all aspects of well-being for both patients and carers. In addition, they underline the need for updated PAH guidelines that address these needs.

Footnotes

  • This article has supplementary material available from err.ersjournals.com

  • Full survey results, along with a call to action, are available at www.phaeurope.org/projects-activities/pah-patient-and-carer-survey

  • Support Statement: All authors are members of the International PAH Patient And Carer Survey Steering Committee and have received honoraria and travel expenses from Actelion that were paid either to them or to their institution.

  • Conflict of interest: Disclosures can be found alongside the online version of this article at err.ersjournals.com

  • Provenance: Publication of this peer-reviewed article was supported by Actelion Pharmaceuticals Ltd, Switzerland (principal sponsor, European Respiratory Review issue 130).

  • Received August 27, 2013.
  • Accepted October 16, 2013.
  • ©ERS 2013

ERR articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 3.0.

View Full Text
PreviousNext
Back to top
View this article with LENS
Vol 22 Issue 130 Table of Contents
  • Table of Contents
  • Table of Contents (PDF)
  • Cover (PDF)
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Understanding the impact of pulmonary arterial hypertension on patients' and carers' lives
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Understanding the impact of pulmonary arterial hypertension on patients' and carers' lives
Loïc Guillevin, Iain Armstrong, Rino Aldrighetti, Luke S. Howard, Henrik Ryftenius, Aryeh Fischer, Sandra Lombardi, Sean Studer, Pisana Ferrari
European Respiratory Review Dec 2013, 22 (130) 535-542; DOI: 10.1183/09059180.00005713

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Understanding the impact of pulmonary arterial hypertension on patients' and carers' lives
Loïc Guillevin, Iain Armstrong, Rino Aldrighetti, Luke S. Howard, Henrik Ryftenius, Aryeh Fischer, Sandra Lombardi, Sean Studer, Pisana Ferrari
European Respiratory Review Dec 2013, 22 (130) 535-542; DOI: 10.1183/09059180.00005713
Reddit logo Technorati logo Twitter logo Connotea logo Facebook logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Introduction
    • Key findings from the international survey
    • Implications for the future management of PAH
    • Conclusion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Pulmonary pharmacology and therapeutics
  • Pulmonary vascular disease
  • Respiratory clinical practice
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Role of air pollutants in airway epithelial barrier dysfunction
  • E-cigarettes and nicotine abstinence
  • Lung imaging in cystic fibrosis
Show more Review

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERR

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising
  • Sponsorship

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN: 0905-9180
Online ISSN: 1600-0617

Copyright © 2023 by the European Respiratory Society